Low Transforming Growth Factor-β Pathway Activity in Cervical Adenocarcinomas

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cervical cancer is a major global health issue for women.
• Adenocarcinoma (AC) histology is increasing and linked to poorer outcomes than squamous cell carcinoma (SCC).
• Transforming growth factor-beta (TGF-β) typically suppresses tumors but can be co-opted by cancer cells, prompting interest in TGF-β inhibitors.

Purpose of the Study:

• To investigate the differential roles of the TGF-β signaling pathway in cervical SCC and AC.
• To identify potential therapeutic strategies targeting the TGF-β pathway in different cervical cancer subtypes.

Main Methods:

• Analysis of RNA-sequencing data from The Cancer Genome Atlas (TCGA) using a TGF-β response signature.
• Immunohistochemical analysis of TGF-β signaling proteins (TβR1/2, SMAD4, pSMAD2, PAI-1, αvβ6, MMP2/9) in a cohort of 62 AC patients.
• Correlation of protein expression with patient survival and comparison between SCC and AC patient samples.

Main Results:

• TGF-β pathway analysis revealed distinct clustering of SCC and AC subtypes.
• In AC, low TβR2 and SMAD4 expression correlated with worse survival; high PAI-1 and αvβ6 also predicted poorer outcomes.
• AC samples showed lower expression of pSMAD2, SMAD4, PAI-1, and αvβ6 compared to SCC samples.

Conclusions:

• The TGF-β pathway appears to have tumor-inhibitory effects in AC, making TGF-β inhibitors potentially unsuitable.
• High PAI-1 and αvβ6 expression in AC correlates with poor prognosis, suggesting potential utility for inhibitors in specific AC subsets.
• TGF-β inhibitors may be more relevant for SCC treatment, based on observed expression patterns and correlations.